cremophor EL

solvent for Althesin & Propanidid implicated as possible cause of similar adverse effects polyethoxylated castor oil; RN given refers to cpd with unknown MF; see also records for cremophor & cremophor A

Also Known As:

Networked: 182 relevant articles (8 outcomes, 23 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Ng, Dennis K P: 4 articles (10/2011 - 12/2007)
2.	Fong, Wing-Ping: 4 articles (10/2011 - 12/2007)
3.	Sparreboom, Alex: 4 articles (01/2006 - 06/2003)
4.	Beijnen, J H: 4 articles (11/2001 - 07/2000)
5.	Colson, Yolonda L: 3 articles (05/2015 - 02/2009)
6.	Grinstaff, Mark W: 3 articles (05/2015 - 02/2009)
7.	Liu, Rong: 3 articles (05/2015 - 02/2009)
8.	Luo, Juntao: 3 articles (04/2015 - 06/2010)
9.	Wei, Yuquan: 3 articles (04/2015 - 01/2012)
10.	Gelderblom, Hans: 3 articles (05/2009 - 06/2003)

Related Diseases

1.	Neoplasms (Cancer) 12/20/2010 - "In vivo studies, PTX-loaded Pluronic nanoparticles were observed with higher anti-tumor efficacy compared with PTX formulated in Cremophor EL." 10/01/2009 - "PTX-30W reduced the number of metastatic nodules and tumor volume significantly more than did conventional PTX dissolved in Cremophor EL (PTX-Cre), and prolonged the survival time (P < 0.05). " 06/19/2006 - "This formulation was designed to overcome vehicle toxicity associated with the traditional Cremophor EL-based formulation and to provide the added advantages of prolonged systemic circulation time and selective targeting of the FR, which is frequently overexpressed on epithelial cancer cells. " 03/10/2006 - "Finally, PTX was less toxic to the tumor-bearing mice when formulated in HGC nanoparticles than when formulated with Cremophor EL." 11/01/2004 - "Animals that received a single-dose intratumoral injection of Tx-NPs-Tf (Tx dose= 4 mg/kg) demonstrated complete tumor regression and greater survival rate than those that received either Tx-NPs or Tx-Cremophor EL formulation. "
2.	Breast Neoplasms (Breast Cancer) 09/01/2011 - "We report the first case of Cremophor EL-induced cutaneous lupus erythematosus-like reaction in a 40-year-old female undergoing treatment for breast cancer. " 03/01/2005 - "Paclitaxel in a novel formulation containing less Cremophor EL as first-line therapy for advanced breast cancer: a phase II trial." 11/01/2009 - "When administered orally to rats bearing chemically induced breast cancer, nanoparticles were equally effective/better than intravenous paclitaxel in cremophor EL at 50% lower dose. " 05/01/1997 - "Human breast cancer MCF-7 wild-type (WT) and resistant (TH) cell lines were cultured in whole human plasma to study anthracycline retention after treatment with different combinations of PTX, Cremophor EL (CEL) (PEG35 castor oil; BASF, Parsippany, NJ), and DOX. " 10/01/2005 - "In vitro and in vivo data on breast cancer cells and xenografts in nude mice indicate that paclitaxel nanosomes are less toxic and much more effective than paclitaxel in Cremophor EL (Taxol). "
3.	Body Weight (Weight, Body) 11/01/1996 - "The rats were injected subcutaneously with 50 mg/kg (body weight) of CsA or with equal volume of the vehicle, Cremophor-EL, for 7 consecutive days. " 09/01/2001 - "The decrease in body weight was greater for paclitaxel in Cremophor EL than for liposomal paclitaxel, but hematological toxicity was similar. " 03/01/1993 - "A dose of 50 mg/kg (body weight) of cyclosporine and an equal volume of vehicle (cremophor-EL) were injected into the rats subcutaneously for 7 or 11 consecutive days. " 12/01/2008 - "These combined features resulted in the following advantages over paclitaxel/Cremophor EL: greater tumor targeting (16-times higher and more sustained concentration in omental tumors), lower toxicity to intestinal crypts and less body weight loss, greater therapeutic efficacy (longer survival and higher cure rate), and greater convenience (less frequent dosing). " 09/01/2001 - "Paclitaxel in liposomes or Cremophor EL was administered to rats at doses of 20 or 40 mg/kg. Body weight and absolute neutrophil count were determined daily. "
4.	Leukemia L1210 08/01/1995 - "Although cremophor EL shows significantly greater activity than verapamil in VP-16 cytotoxicity enhancement in vitro, it is ineffective when added to VP-16 therapy of mice bearing L1210 leukemia."
5.	Hemolysis 05/20/2003 - "The hemolysis test of PEtOz-PCL performed in vitro indicated that the toxicity of PEtOz-PCLs to lipid membrane was not significant compared with Tween 80, and was comparable to that observed with Cremophore EL. " 09/01/2012 - "The PAA-PPA was safer than Tween-80 and Cremophor EL (CrmEL) as an injectable pharmaceutical adjuvant for ATPR as indicated by the hemolysis and cytotoxicity studies. " 07/06/2009 - "Hemolysis and cytotoxicity studies showed that OSA was safer than Tween-80 and Cremophor EL as an injectable pharmaceutic adjuvant for PTX. " 07/01/2001 - "In vitro hemolysis and buffer capacity studies with the novel marine anticancer agent kahalalide F and its reconstitution vehicle cremophor EL/ethanol." 01/01/2012 - "The conjugate exhibited about 2% hemolysis at 10 mg/mL, compared with 56% for Tween 80(®) at 0.4 mg/mL, and 33% for Cremophor EL(®) at 10 mg/mL. In addition, the conjugate was further tested for in vitro cytotoxicity and in vivo antitumor efficacy on the human non-small cell lung cancer cell line NCI-H460. "

Related Drugs and Biologics

1.	Paclitaxel (Taxol)
2.	Ethanol (Ethyl Alcohol)
3.	130-nm albumin-bound paclitaxel
4.	Verapamil (Calan)
5.	Lipoproteins (Lipoprotein)
6.	Etoposide (VP 16)
7.	Doxorubicin (Adriamycin)
8.	Castor Oil (Oil, Castor)
9.	Pharmaceutic Adjuvants (Pharmaceutic Adjuvant)
10.	Polysorbates (PSML)

Related Therapies and Procedures

1.	Heterologous Transplantation (Xenotransplantation)
2.	Injections
3.	Drug Therapy (Chemotherapy)
4.	Aftercare (After-Treatment)
5.	Premedication